4.0
17. Mai 2026
Ehemaliger Mitarbeiter, mehr als 10 Jahre
Boston, MA
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
Good company benefits. Strong leadership in Oncology Account Group segment. Pipeline from 2029 and beyond looks strong. The Oncology Key Account Role offers a lot of diverse experiences and is an asset to the teams
Kontras
Does not pay at high level in comparison to other smaller companies in sales/ commercial side.